Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.

Key facts

Study ID

NCT07018492

Run by

Shionogi

People needed

32

Starts

2025-08-30

Expected to finish

2025-11-26

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Division of Clinical Pharmacology, University of Miami — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• Texas Liver Institute — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.